These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
74 related items for PubMed ID: 9463266
1. [Stavudine and lamivudine. Two new nucleoside analogues efficient against HIV]. Gerstoft J. Ugeskr Laeger; 1998 Jan 19; 160(4):457-61. PubMed ID: 9463266 [No Abstract] [Full Text] [Related]
2. Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV. Rey D, L'Héritier A, Lang JM. Clin Infect Dis; 2002 Feb 01; 34(3):418-9. PubMed ID: 11774091 [No Abstract] [Full Text] [Related]
3. Computational models of antiviral toxicity. Samuels DC. Curr Opin Drug Discov Devel; 2007 Jan 01; 10(1):43-8. PubMed ID: 17265740 [Abstract] [Full Text] [Related]
4. Developing countries need better antiretroviral drugs. Mykén N, Sundbeck B, Mpumilwa G, Andersson R. J Int Assoc Physicians AIDS Care (Chic); 2009 Jan 01; 8(1):23-4. PubMed ID: 19171914 [No Abstract] [Full Text] [Related]
5. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Songa PM, Castelnuovo B, Mugasha EB, Ocama P, Kambugu A. Clin Infect Dis; 2007 Aug 15; 45(4):514-7. PubMed ID: 17638205 [Abstract] [Full Text] [Related]
9. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. Nelson M, Azwa A, Sokwala A, Harania RS, Stebbing J. AIDS; 2008 Jul 11; 22(11):1374-6. PubMed ID: 18580619 [Abstract] [Full Text] [Related]
12. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine. Fisher M. AIDS; 1998 Jul 11; 12 Suppl 3():S9-16. PubMed ID: 15168718 [Abstract] [Full Text] [Related]
13. Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir. Anderson RD. Antivir Ther; 1998 Jul 11; 3 Suppl 4():63-4. PubMed ID: 10723514 [Abstract] [Full Text] [Related]
17. ddI and d4T plus protease inhibitors. GMHC Treat Issues; 1996 Nov 05; 10(11):8-9. PubMed ID: 11364012 [Abstract] [Full Text] [Related]
18. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cécile A, Delaugerre C, Damond F, Marcelin AG, Matheron S, Simon A, Valantin MA, Katlama C, Brun-Vézinet F. Antivir Ther; 2002 Sep 05; 7(3):211-8. PubMed ID: 12487389 [Abstract] [Full Text] [Related]
19. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo]. Mouhari-Touré A, Saka B, Kombat K, Tchangaï-Walla K, Pitche P. Bull Soc Pathol Exot; 2008 Dec 05; 101(5):404-6. PubMed ID: 19192611 [Abstract] [Full Text] [Related]